Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. - Wikidata - wikimedia - TriplyDB

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

http://www.wikidata.org/entity/Q33385878

about

Getting TRAIL back on track for cancer therapy Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cells Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Harnessing the cell death pathway for targeted cancer treatment.The therapeutic potential of TRAIL receptor signalling in cancer cells.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Death receptors as targets in cancer Targeting TRAIL in the treatment of cancer: new developments.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.Phage display-derived human antibodies in clinical development and therapy Targeting apoptosis signaling in pancreatic cancer TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.Death Receptors: New Opportunities in Cancer Therapy.Developing TRAIL/TRAIL death receptor-based cancer therapies.

P2860

Q27027460-81A8458B-30E1-47FE-A9D2-555F841B65E3 Q28391040-48BA9BEB-1AE2-4902-B7C0-9D653EB8712F Q28397571-E9DDEC2F-09BD-48A4-B8FD-87F6B2B90DA4 Q28817517-48503FE1-BD92-4029-B3ED-6E87BF8E60B3 Q33658593-D9E4A263-D6EF-489D-A0D7-3DBB3CD04AE8 Q33863928-2ACF1432-6CA1-4EB7-A924-775409616317 Q34429203-3159A1CE-FB76-485C-A420-30787B7B440E Q34433792-74748110-CF93-45FF-A3E2-4C2E69F168DA Q34980866-22D60C08-4512-4915-9A68-A0B759D60F00 Q35595688-A703A6D6-A65A-4883-84F4-2CDAF3CE84A3 Q35853714-5B2FF9DE-4013-4950-8C99-DD6A4BA6B9CA Q35951059-094C5F1B-0A71-4579-82AF-70F9684AEF59 Q36180733-293EA989-21CE-4EF9-8F7D-5201D401857F Q36482809-0015FA0F-A982-413C-B403-9C8F22B2C625 Q37012681-D15FB708-7FD5-46C7-8F71-BFAB3C6B6A2D Q37071019-F6EB5C7C-1F77-4A9D-A885-CA3A3AE0D46F Q37114025-7E8BDBE5-9126-4754-8E25-3E1D0F2836C1 Q37311413-12BF2413-F6A6-414D-9D90-3A7AEF35076B Q37621564-CCE180F6-C751-4721-A8AA-07CD879BE8FA Q37785559-B4475B0B-7A79-40D5-ACDC-B448CE8C351E Q37799251-8E83B26F-C7E4-4E47-A4FD-73E4AF71D865 Q37913356-928FA4FC-A019-45CB-B0D3-2CE0397C1D9F Q37942090-125CFC19-EC02-4D54-B37A-B6340D1B6905 Q37962655-B9CC9CCB-C115-43DF-8AC2-DD2D4C97C240 Q37972139-6CB8FD11-8967-4EE3-B766-41ABB81603FA Q38103591-EB293C58-D24D-440A-BAA3-DAEF09A20726 Q38500801-D4CD3302-F7CD-4625-A519-044243C5A2BC Q38557486-3B37014C-9D50-4277-9217-C5B20F186865 Q38708598-B873F37F-4E6E-449F-A34F-9D8AA272149B Q39003096-8DD5F52F-099D-44B7-8DFB-CF13A90884E7 Q39149515-5CFFF19B-5558-4B4C-9496-3F4547E14232 Q39179377-6A5B02E2-0A7A-422D-955B-9C38EE790882 Q39455419-DE34EE21-6A1C-4525-81C6-8374987CADFA Q39586282-6CAE99E9-7464-479A-A60A-EDE647CC93E1 Q41416393-07473A9F-1B73-4FD2-89D0-0F1CE90A112E Q42040100-2204971F-C0B6-467E-A372-C53F57CEDA71 Q42623198-C54B0C67-1B1E-4771-87B0-7B1D25F06BB3 Q47108799-1E295ED5-C8F8-44EA-951A-1FA00CFB821D Q53701901-5CF90821-9304-4501-B5CC-869D680DF1BC

P2860

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

http://www.wikidata.org/entity/Q33385878

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@ast

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@en

type

label

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@ast

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@en

prefLabel

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@ast

Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.

@en

P1433

Q33385878-EA4B6462-393D-410A-A015-0F44E7639F81

P1476

Q33385878-51051C1D-E3AC-49DD-961D-FD072E99A63D

P2093

Q33385878-1F12C1C7-6CE0-43CB-9299-4146B31C576F

Q33385878-3F28A8C3-3932-4C59-B17A-E8AA1D1C2256

Q33385878-8210A1B5-0016-42FB-BD08-8004E0432AB2

Q33385878-837B2A3E-0CD7-47DE-BFC6-909EA96FD5DF

Q33385878-8DC5B0E4-8AB1-41BE-ADE8-BE4B0DC63AB2

Q33385878-98BEB91D-33B8-4992-A335-CD8D6D81F1AF

Q33385878-B44AE763-56A4-419C-BD08-FAC573D47088

Q33385878-E5BBC32D-2DF7-43D6-ADC4-F544B749E4A7

P304

Q33385878-E49F8096-A10D-4873-B6B9-7470111BA29E

P31

Q33385878-6537E867-A5AB-4497-84E7-B2073E7F50D3

P356

Q33385878-F53AFDCF-ED89-4C4C-929F-949B9B5FEF87

P407

Q33385878-CC78FE59-737E-4014-89BB-551C6D3E5D4B

P433

Q33385878-84DFEDA0-A25F-46D6-ADAA-6FE607016997

P478

Q33385878-F71A5B71-D101-43DF-8D1F-1AF57AB7DA73

P50

Q33385878-3F546B57-45C3-48DF-848C-9D9C1AE60B01

Q33385878-56D1129B-C371-4A5C-B3AF-73D386F3B04E

P577

Q33385878-8F20FBE6-C32E-453F-A123-90E2ADD2E3E4

P698

Q33385878-AEBD6649-DB17-459F-8605-892B1021A489

P921

Q33385878-2DEA9E58-3FA8-4D9A-BEDD-A288A6044500

P356

1078-0432.CCR-09-0996

P1433

Clinical Cancer Research

P1476

Mapatumumab, a fully human ago ...... and cisplatin: a phase I study

@en

P2093

Constantijne H Mom

http://www.w3.org/2001/XMLSchema#string

Corina N A M Oldenhuis

http://www.w3.org/2001/XMLSchema#string

Ferry A L M Eskens

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

Norma Lynn Fox

http://www.w3.org/2001/XMLSchema#string

Renée Miceli

http://www.w3.org/2001/XMLSchema#string

Stefan Sleijfer

http://www.w3.org/2001/XMLSchema#string

Walter J Loos

http://www.w3.org/2001/XMLSchema#string

P304

5584-5590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0996

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jourik A Gietema

Elisabeth de Vries

P577

2009-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19690193

http://www.w3.org/2001/XMLSchema#string

P921